Scandinavian ChemoTech AB Series B (ST:CMOTEC-B) — Market Cap & Net Worth
Market Cap & Net Worth: Scandinavian ChemoTech AB Series B (CMOTEC-B)
Scandinavian ChemoTech AB Series B (ST:CMOTEC-B) has a market capitalization of $10.22 Million (Skr94.97 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #26836 globally and #584 in its home market, demonstrating a -2.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scandinavian ChemoTech AB Series B's stock price Skr3.99 by its total outstanding shares 23802312 (23.80 Million). Analyse cash efficiency ratio of Scandinavian ChemoTech AB Series B to see how efficiently the company converts income to cash.
Scandinavian ChemoTech AB Series B Market Cap History: 2016 to 2026
Scandinavian ChemoTech AB Series B's market capitalization history from 2016 to 2026. Data shows change from $116.69 Million to $10.22 Million (-22.93% CAGR).
Scandinavian ChemoTech AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scandinavian ChemoTech AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.70x
Scandinavian ChemoTech AB Series B's market cap is 0.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $116.69 Million | $2.08 Million | -$8.14 Million | 55.99x | N/A |
| 2017 | $57.25 Million | $27.24K | -$8.33 Million | 2101.32x | N/A |
| 2018 | $28.40 Million | $560.00K | -$4.80 Million | 50.72x | N/A |
| 2019 | $29.06 Million | $556.00K | -$12.59 Million | 52.27x | N/A |
| 2020 | $34.71 Million | $131.00K | -$11.66 Million | 264.95x | N/A |
| 2021 | $43.65 Million | $49.00K | -$17.74 Million | 890.78x | N/A |
| 2022 | $12.94 Million | $473.00K | -$22.75 Million | 27.35x | N/A |
| 2023 | $6.92 Million | $2.82 Million | -$21.09 Million | 2.45x | N/A |
| 2024 | $4.59 Million | $6.57 Million | -$13.72 Million | 0.70x | N/A |
Competitor Companies of CMOTEC-B by Market Capitalization
Companies near Scandinavian ChemoTech AB Series B in the global market cap rankings as of May 4, 2026.
Key companies related to Scandinavian ChemoTech AB Series B by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Scandinavian ChemoTech AB Series B Historical Marketcap From 2016 to 2026
Between 2016 and today, Scandinavian ChemoTech AB Series B's market cap moved from $116.69 Million to $ 10.22 Million, with a yearly change of -22.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr10.22 Million | -20.52% |
| 2025 | Skr12.86 Million | +180.45% |
| 2024 | Skr4.59 Million | -33.70% |
| 2023 | Skr6.92 Million | -46.53% |
| 2022 | Skr12.94 Million | -70.36% |
| 2021 | Skr43.65 Million | +25.76% |
| 2020 | Skr34.71 Million | +19.42% |
| 2019 | Skr29.06 Million | +2.32% |
| 2018 | Skr28.40 Million | -50.38% |
| 2017 | Skr57.25 Million | -50.94% |
| 2016 | Skr116.69 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Scandinavian ChemoTech AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.22 Million USD |
| MoneyControl | $10.22 Million USD |
| MarketWatch | $10.22 Million USD |
| marketcap.company | $10.22 Million USD |
| Reuters | $10.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more